NASDAQ:XFOR X4 Pharmaceuticals - XFOR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.04 0.00 (0.00%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.01▼$1.0750-Day Range$0.69▼$1.8552-Week Range$0.65▼$2.41Volume658,543 shsAverage Volume768,538 shsMarket Capitalization$72.01 millionP/E RatioN/ADividend YieldN/APrice Target$6.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability X4 Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside559.3% Upside$6.86 Price TargetShort InterestHealthy1.81% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.43) to ($0.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.74 out of 5 starsMedical Sector38th out of 1,028 stocksBiological Products, Except Diagnostic Industry8th out of 168 stocks 3.5 Analyst's Opinion Consensus RatingX4 Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.86, X4 Pharmaceuticals has a forecasted upside of 559.3% from its current price of $1.04.Amount of Analyst CoverageX4 Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.81% of the outstanding shares of X4 Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverX4 Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in X4 Pharmaceuticals has recently decreased by 20.89%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldX4 Pharmaceuticals does not currently pay a dividend.Dividend GrowthX4 Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreX4 Pharmaceuticals has received a 71.51% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for mental health" and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for X4 Pharmaceuticals is -0.85. Previous Next 2.4 News and Social Media Coverage News SentimentX4 Pharmaceuticals has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for X4 Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for XFOR on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, X4 Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders95.90% of the stock of X4 Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.46% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($1.43) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of X4 Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of X4 Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioX4 Pharmaceuticals has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About X4 Pharmaceuticals (NASDAQ:XFOR) StockX4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.Read More Receive XFOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address XFOR Stock News HeadlinesJanuary 31, 2023 | finance.yahoo.comWhat Makes X4 Pharmaceuticals (XFOR) a New Buy StockJanuary 29, 2023 | americanbankingnews.comShort Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Declines By 20.9%February 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 21, 2023 | forbes.comX4 PharmaceuticalsJanuary 14, 2023 | seekingalpha.comXFOR X4 Pharmaceuticals, Inc.December 12, 2022 | finance.yahoo.comX4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic NeutropeniaDecember 7, 2022 | finance.yahoo.comX4 Pharmaceuticals Prices $65.0 Million Public OfferingNovember 30, 2022 | finance.yahoo.comX4 Pharmaceuticals Shares Tumble After Phase 3 Data From Rare Immune Deficiency CandidateFebruary 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.November 30, 2022 | seekingalpha.comX4 Pharma sheds 16% even as rare disease therapy meets main goal in Phase 3 trialNovember 30, 2022 | finance.yahoo.comX4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM SyndromeNovember 17, 2022 | finance.yahoo.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) most popular amongst individual investors who own 40% of the shares, institutions hold 34%November 8, 2022 | finance.yahoo.comX4 Pharmaceuticals to Present at Stifel Healthcare ConferenceNovember 5, 2022 | seekingalpha.comX4 Pharmaceuticals, Inc. (XFOR) Q3 2022 Earnings Call TranscriptNovember 3, 2022 | msn.comX4 Pharmaceuticals: Q3 Earnings InsightsNovember 3, 2022 | finance.yahoo.comX4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateOctober 26, 2022 | finance.yahoo.comX4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial OfficerOctober 20, 2022 | finance.yahoo.comX4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022October 5, 2022 | finance.yahoo.comX4 Pharma Highlights New Data Supporting Mavorixafor's Broad Potential In Chronic NeutropeniaSeptember 27, 2022 | seekingalpha.comX4 stock rises 10% as mavorixafor shows promise in trial for white blood cell disorderSeptember 27, 2022 | finance.yahoo.comX4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)August 18, 2022 | finance.yahoo.comAll You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to BuyAugust 8, 2022 | finance.yahoo.comX4 Pharmaceuticals to Present at Canaccord Genuity’s 42nd Annual Growth ConferenceAugust 7, 2022 | seekingalpha.comX4 Pharmaceuticals, Inc.'s (XFOR) CEO Dr. Paula Ragan on Q2 2022 Results - Earnings Call TranscriptAugust 7, 2022 | seekingalpha.comX4 Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationAugust 4, 2022 | finance.yahoo.comX4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateAugust 4, 2022 | finance.yahoo.comX4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive XFOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address XFOR Company Calendar Last Earnings11/04/2021Today2/05/2023Next Earnings (Estimated)3/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XFOR CUSIPN/A CIK1501697 Webwww.x4pharma.com Phone(857) 529-8300FaxN/AEmployees83Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.86 High Stock Price Forecast$10.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+559.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-184.37% Return on Assets-92.38% Debt Debt-to-Equity Ratio0.30 Current Ratio2.99 Quick Ratio2.99 Sales & Book Value Annual Sales$3 million Price / Sales24.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book0.40Miscellaneous Outstanding Shares69,240,000Free Float2,839,000Market Cap$72.01 million OptionableNot Optionable Beta0.50 Key ExecutivesPaula S. RaganPresident, Chief Executive Officer & DirectorMary DiBiaseChief Operating OfficerAdam S. MostafaChief Financial Officer & TreasurerMurray W. StewartIndependent Director & Chief Medical OfficerArt TaverasChief Scientific OfficerKey CompetitorsTalaris TherapeuticsNASDAQ:TALSOrchard TherapeuticsNASDAQ:ORTXAmbrx BiopharmaNYSE:AMAMBrainstorm Cell TherapeuticsNASDAQ:BCLIMiNK TherapeuticsNASDAQ:INKTView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 21,700 shares on 2/2/2023Ownership: 0.000%Tri Locum Partners LPBought 765,706 shares on 11/15/2022Ownership: 3.617%Parkman Healthcare Partners LLCBought 950,000 shares on 11/15/2022Ownership: 1.372%BlackRock Inc.Bought 11,930 shares on 11/15/2022Ownership: 0.418%Citadel Advisors LLCBought 58,600 shares on 11/15/2022Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions XFOR Stock - Frequently Asked Questions Should I buy or sell X4 Pharmaceuticals stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XFOR shares. View XFOR analyst ratings or view top-rated stocks. What is X4 Pharmaceuticals' stock price forecast for 2023? 5 brokers have issued 12-month price objectives for X4 Pharmaceuticals' stock. Their XFOR share price forecasts range from $3.00 to $10.00. On average, they anticipate the company's stock price to reach $6.86 in the next twelve months. This suggests a possible upside of 559.3% from the stock's current price. View analysts price targets for XFOR or view top-rated stocks among Wall Street analysts. How have XFOR shares performed in 2023? X4 Pharmaceuticals' stock was trading at $0.9930 at the start of the year. Since then, XFOR stock has increased by 4.7% and is now trading at $1.04. View the best growth stocks for 2023 here. Are investors shorting X4 Pharmaceuticals? X4 Pharmaceuticals saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 1,250,000 shares, a decrease of 20.9% from the December 31st total of 1,580,000 shares. Based on an average trading volume of 1,270,000 shares, the short-interest ratio is presently 1.0 days. View X4 Pharmaceuticals' Short Interest. When is X4 Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023. View our XFOR earnings forecast. How were X4 Pharmaceuticals' earnings last quarter? X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.04. During the same quarter last year, the company earned ($0.87) EPS. What other stocks do shareholders of X4 Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX). What is X4 Pharmaceuticals' stock symbol? X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR." Who are X4 Pharmaceuticals' major shareholders? X4 Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adam S Mostafa, Adam S Mostafa, Derek M Meisner, Derek M Meisner, Paula Ragan and Renato Skerlj. View institutional ownership trends. How do I buy shares of X4 Pharmaceuticals? Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is X4 Pharmaceuticals' stock price today? One share of XFOR stock can currently be purchased for approximately $1.04. How much money does X4 Pharmaceuticals make? X4 Pharmaceuticals (NASDAQ:XFOR) has a market capitalization of $72.01 million and generates $3 million in revenue each year. The company earns $-88,700,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. How can I contact X4 Pharmaceuticals? X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The official website for the company is www.x4pharma.com. The company can be reached via phone at (857) 529-8300 or via email at ir@arsanis.com. This page (NASDAQ:XFOR) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.